3 research outputs found

    Potentiation of anticonvulsant activity of phenytoin by calcium channel blockers (verapamil and amlodipine) against maximal electroshock seizures in rats

    Get PDF
    Background: The objective of this work was to study the anticonvulsant activity of calcium channel blockers verapamil and amlodipine and their interaction with an established antiepileptic drug diphenylhydantoin (DPH) in experimental model of epilepsy in albino rats.Methods: Maximal electroshock (MES) convulsions were induced by electroconvulsiometer and different phases of MES were noted in control and drug treated groups. Effect of different doses of verapamil (dose-5, 10 and 15 mg/kg), amlodipine (dose-2.5, 3 and 3.5 mg/kg) and DPH (dose-0.5 and 1 mg/100 g) on MES was studied. Finally, effect of combined treatment consisting of non-protective dose of DPH with different doses of verapamil and amlodipine were also studied on MES induced seizures.Results: Combination of non-protective dose (0.5 mg/100 g) of DPH with all the three doses of verapamil and amlodipine offered significant protection against MES induced seizures.Conclusions: From the present investigation, it may be concluded that the dose of DPH may be reduced in an antiepileptic individual who is on verapamil and amlodipine therapy

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
    corecore